TrialCancer immunology, immunotherapy : CII2025

Efficacy and safety of PD-1 blockade-activated neoantigen specific cellular therapy for advanced relapsed non-small cell lung cancer.

Yun Qiao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.